National registry of haemophilia and other coagulopathies: A multisector initiative in the Colombian Health System

被引:2
作者
Alvis, Luisa Fernanda [1 ]
Sanchez, Patricia [1 ]
Acuna, Lizbeth [1 ]
Escobar, German [2 ]
Linares, Adriana [3 ]
Solano, Maria Helena [4 ]
Robledo, Sergio [5 ]
机构
[1] Fondo Colombiano Enfermedades Alto Costo, Cuenta Alto Costo, Carrera 45 103-34 Off 802, Bogota, Colombia
[2] Minist Salud & Protecc Social, Oficina Calidad, Bogota, Colombia
[3] Univ Nacl Colombia, Asociac Colombiana Hematol & Oncol ACHO, Asociac Colombiana Hematol & Oncol Pediat ACHOP, Bogota, Colombia
[4] Fdn Univ Ciencias Salud FUCS, Asociac Colombiana Hematol & Oncol ACHO, Bogota, Colombia
[5] Colhemofil Colombian League Hemophilia & Other Bl, Bogota, Colombia
关键词
blood coagulation disorders; decision-making; haemophilia; inherited; rare diseases; registries; EUROPEAN PRINCIPLES; A PATIENTS; PROPHYLAXIS; INHIBITORS; CARE; GUIDELINES; MANAGEMENT; COSTS;
D O I
10.1111/hae.14138
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Haemophilia is an orphan and high-cost disease worldwide and, especially in middle-income countries as Colombia. Given its burden of disease, in 2014, a national administrative registry was created to centralize demographic, clinical and economic information regarding to haemophilia and other coagulopathies. Objective To describe the building and implementation processes of the Colombian registry of haemophilia and other coagulopathies. Methods The 'consensus conference' methodology was used to design the registry. It was a multisector process, which included different actors of the health system (healthcare payers and providers, government institutions, academic and scientific organizations and patients). Results Colombia's national registry includes 95 variables, grouped in four sections: (1) sociodemographic data, (2) clinical condition, (3) economic costs, and (4) administrative updates. According to a resolution, stated by the Ministry of Health, payers and providers of healthcare must report annually to the registry the information of new and existing patients with coagulopathies. Conclusions A national registry serves as an organized and interactive system for monitoring morbidity and mortality, assessing healthcare access and its impact on disease complications, as well as associated costs to medical assistance. Furthermore, registry information can guide a rational making decision process to use economic resources efficiently. On the other hand, data about orphan diseases can encourage health research and evidence-based care to improve quality of life and reduce associated disability.
引用
收藏
页码:E254 / E261
页数:8
相关论文
共 36 条
[1]   Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy [J].
Abbonizio, F. ;
Giampaolo, A. ;
Coppola, A. ;
Arcieri, R. ;
Hassan, H. J. .
HAEMOPHILIA, 2014, 20 (04) :e243-e250
[2]  
Acharya SS, 2016, AM J MANAG CARE, V22, pS116
[3]  
[Anonymous], 2012, Technical Report, P1
[4]  
[Anonymous], 2012, OFFICIAL DIARY REPUB
[5]   Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report [J].
Astermark, J. ;
Altisent, C. ;
Batorova, A. ;
Diniz, M. J. ;
Gringeri, A. ;
Holme, P. A. ;
Karafoulidou, A. ;
Lopez-Fernandez, M. F. ;
Reipert, B. M. ;
Rocino, A. ;
Schiavoni, M. ;
von Depka, M. ;
Windyga, J. ;
Fijnvandraat, K. .
HAEMOPHILIA, 2010, 16 (05) :747-766
[6]   Haemophilia care in Latin America: Assessment and perspectives [J].
Boadas, Apsara ;
Ozelo, Margareth C. ;
Solano, Maria ;
Berges, Adolfina ;
Ruiz-Saez, Arlette ;
Linares, Adriana ;
Luis Lamas, Jose ;
Aparicio, Rafael ;
Aversa, Luis ;
Baques, Alejandra ;
Estrada, Armando ;
Herrejon, Misael ;
Mancia, Ana ;
Nieves-Paulino, Rosa ;
Pinto, Ieda ;
Prezoti, Alessandra ;
Soto, Veronica ;
Ugalde, Dani .
HAEMOPHILIA, 2018, 24 (06) :E395-E401
[7]  
Carlos-Rivera F, 2016, GAC MED MEX, V152, P19
[8]   Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks [J].
Castaman, Giancarlo ;
Linari, Silvia .
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (07) :567-576
[9]   COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA [J].
Castro Jaramillo, Hector Eduardo ;
Moreno Viscaya, Mabel ;
Mejia, Aurelio E. .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (05) :337-347
[10]  
Chen SL, 2016, AM J MANAG CARE, V22, pS126